News and Announcements
AIMEDICS – CEO Interview
- Published September 24, 2012 10:56AM UTC
- Publisher Wholesale Investor
- Categories Executive Interviews
AIMEDICS has developed the HypoMon which is the world’s first non-invasive night time low blood glucose management system. More than 11 million diabetic insulin users in the developed world suffer from bouts of dangerously low blood glucose several nights per month. Independent USA market research indicates that the HypoMon is a unique product addressing a recognised unmet need with a market opportunity exceeding $2 billion pa.
Executive Interviews
Everything is now competing for the same dollar
Key takeaways As recently as 2022, Germany and Japan could borrow for 30 years at close to zero. That world is gone, and AI is now bidding for what is left. Over the past fortnight, I listened to founders, operators and allocators describe where their industries are heading. They covered four very different frontiers. Each […]
Australia has not held 90 days of fuel since 2012. The fix may start at a sewage plant.
A decommissioned council treatment site in Bundaberg is being built into a $188.9 million biorefinery. Its managing director is candid that the largest revenue line is not yet contracted. Australia has not met its international 90-day fuel reserve obligation since 2012. Around 90 per cent of the country’s liquid fuel is imported. Andy Whitmore, Managing […]
Forget Startups: Why Magnetic Alliance is Betting on “Boring” Mid-Market Turnarounds
While Australia’s venture capital scene spent years chasing unprofitable tech startups and speculative high-growth plays, Mark Lim was quietly taking a radically different path. The Managing Partner of Magnetic Alliance Capital sees the nation’s richest investment opportunities hiding in plain sight: inside thousands of unglamorous, profitable, but operationally sluggish mid-market businesses. Speaking on Wholesale Investor’s […]
Backed By Leading Investment Groups and Family Offices
